Treatment with PLX4720 led to significant tumour volume reduction (259 ± 65 mm3, 41% tumour growth inhibition, p < 0.01), whereas dramatic tumour reduction was seen with PLX4720 + anti-PD-1 (160 ± 47 mm3, 61% tumour growth inhibition, p < 0.01) and PLX4720 + anti-PD-L1 (170 ± 67 mm3, 64% tumour growth inhibition, p < 0.01), consistent with our prior work (Fig. 1b). This evidence concerns the gene CD274 and neoplasm.